loading page

CD14/16 Monocyte Profiling in Juvenile Myelomonocytic Leukemia
  • +2
  • Manisha Gadgeel,
  • Shruti BaglaOrcid,
  • Steven Buck,
  • Mark Shamoun,
  • Yaddanapudi Ravindranath
Manisha Gadgeel
Wayne State University School of Medicine
Author Profile
Shruti Bagla
Orcid
Wayne State University
Author Profile
Steven Buck
Children's Hospital of Michigan
Author Profile
Mark Shamoun
Children's Hospital of Michigan
Author Profile
Yaddanapudi Ravindranath
Wayne State University School of Medicine
Author Profile

Peer review status:ACCEPTED

05 May 2020Submission Checks Completed
05 May 2020Assigned to Editor
05 May 2020Submitted to Pediatric Blood & Cancer
07 May 2020Reviewer(s) Assigned
19 May 2020Review(s) Completed, Editorial Evaluation Pending
26 May 2020Editorial Decision: Revise Major
10 Jun 2020Submission Checks Completed
10 Jun 2020Assigned to Editor
10 Jun 20201st Revision Received
11 Jun 2020Reviewer(s) Assigned
15 Jun 2020Review(s) Completed, Editorial Evaluation Pending
19 Jun 2020Editorial Decision: Accept

Abstract

Monocyte subset analysis by flow cytometry has been shown to be a useful diagnostic tool in chronic myelomonocytic leukemia in adults. An increase in the classical monocyte fraction (CD14++/CD16-) greater than 94.0% of total monocytes is considered highly sensitive and specific in distinguishing CMML from other myeloproliferative disorders. In a pilot study of juvenile myelomonocytic leukemia cases, we noted that CD14++/CD16- monocyte fraction was >95% in de novo JMML with somatic PTPN11 mutations but normal in those with monosomy 7 or Noonan syndrome. Monocyte subgroup profiling by itself is not diagnostic of JMML but may distinguish molecular subgroups within JMML.